MONDAY, July 2, 2018 — For patients with previously treated advanced gastric cancer or gastro-esophageal junction cancer, pembrolizumab does not result in a significant improvement in overall survival compared with paclitaxel, according to a study published online June 4 in The Lancet. Kohei Shitara, M.D., from National Cancer Center Hospital East in Kashiwa, Japan, and